Lilly Q2 revenue up 36% to $11.3B, raises FY revenue guidance by $3B

ELI LILLY & Co

2024-Q2 EPS reported $5.76 revenue$20,070,800,000

Q2 revenue $11.30B (+36% YoY); reported EPS $3.28 (+68%), non-GAAP EPS $3.92 (+86%).
FY revenue guidance raised $3B; reported EPS raised $2.05 to $15.10-15.60; non-GAAP EPS raised $2.60 to $16.10-16.60.
Growth driven by Mounjaro, Zepbound, and Verzenio; non-incretin revenue up 17% ex-Baqsimi rights sale.
Pipeline: FDA approval of Kisunla for Alzheimer's; tirzepatide submissions for sleep apnea; positive SUMMIT and QWINT trials.
Announced agreement to acquire Morphic Holding for oral integrin therapies; $5.3B manufacturing investment in Indiana.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.